DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial

Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Cholecystitits

Intervention: Antibiotic treatment (Drug); No antibiotics (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Hadassah Medical Organization

Official(s) and/or principal investigator(s):
Haggi Mazeh, M.D., Principal Investigator, Affiliation: Hadassah Medical Organization
Herbert R Freund, M.D., Study Director, Affiliation: Hadassah Medical Organization

Overall contact:
Haggi Mazeh, M.D., Phone: 00 972 2 5844550, Email: hmazeh@hadassah.org.il

Summary

The treatment of acute cholecystitis includes limited oral intake, antibiotics and early or delayed surgery. To date there are no randomized trials proving the benefit of antibiotic treatment.

The aim of this study is to prospectively and randomly compare between patients that are admitted for acute cholecystitis and treated with or without antibiotics.

Clinical Details

Official title: The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial

Study design: Case Control, Prospective

Detailed description: Cholelithiasis and inflammatory biliary tract disease constitute a major health problem in western countries. Acute cholecystitis is the third major cause of emergency admission to a surgical ward and its incidence increases with increasing age. Acute cholecystitis is defined as acute inflammation of the gallbladder which is commonly caused by gallstones which are impacted in the cystic duct. The treatment of acute cholecystitis varies between different medical centers around the world. In some hospitals, mainly in the US, the most common treatment is early laparoscopic cholecystectomy within 72 hours from the onset of symptoms / admission. However, in the UK and many other centers in Europe the treatment of acute cholecystitis is conservative (NPO, IV fluids and antibiotics) and laparoscopic cholecystectomy is delayed. The reasons for delayed surgery differ between institutions and include the assumption of decreased complications, surgeon and OR availability and schedule, costs, and hospital policy.

A recent metanalysis proved similar safety and efficacy of early and delayed laparoscopic cholecystectomy. The conversion rate, length of operation and complication rate (overall complication rate, intra-abdominal collection, bile leak, and CBD injury) were also comparable.

At Hadassah-Hebrew University Medical Center, Mount Scopus patients with acute cholecystitis are treated conservatively followed by delayed laparoscopic cholecystectomy. Over the years this approach proved to carry relatively low rate of complications, mainly bile duct injuries <1%, without interruption to the busy OR schedule.

Regardless to the lack of evidence based guidelines for the treatment of acute cholecystitis the traditional triad of NPO, IV fluids and antibiotics was adopted at our institution

vis- - vis the higher complication and conversion rate for early cholecystectomy. The

antibiotic treatment is associated with side effects, costs and most important unavoidable development of bacterial drug resistance. However, to date there are no randomized trials proving the superiority of either one of these methods.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

Patients with the diagnosis of mild acute cholecystitis that meet the following:

1. Sonographic (or CT) findings:

1. cholelithiasis or sludge and

2. wall thickening > 4 mm, and

3. positive sonographic Murphy sign,

4. distended gallbladder (optional)

5. pericystic fluid (optional)

2. Additional one of the following:

1. epigastric or RUQ pain

2. fever > 38. 0

3. WBC > 10,000

Exclusion criteria:

1. Age - less than 18 or above 70

2. Pregnant females

3. Unconsentable patients

4. NYHA > 3

5. Use of steroids or immunosuppression

6. Onset of typical abdominal pain for over than 72 hours

7. Hemodynamic instability

8. Fever > 39 or chills

9. Palpable inflammatory RUQ mass

10. Presence of peritonitis on physical examination

11. WBC > 18,000

12. Diastase > 200 (NL 20-100)

13. Bilirubin > 85 (X5 the norm)

14. Multi organ failure

Locations and Contacts

Haggi Mazeh, M.D., Phone: 00 972 2 5844550, Email: hmazeh@hadassah.org.il

Hadassah Medical Organization, Jerusalem 91120, Israel; Recruiting
Arik Tzukert, DMD, Phone: 0097226776095, Email: arik@hadassah.org.il
Hadas Lemberg, PhD, Phone: 0097226777572, Email: lhadas@hadassah.org.il
Additional Information

Related publications:

Yoshida M, Takada T, Kawarada Y, Tanaka A, Nimura Y, Gomi H, Hirota M, Miura F, Wada K, Mayumi T, Solomkin JS, Strasberg S, Pitt HA, Belghiti J, de Santibanes E, Fan ST, Chen MF, Belli G, Hilvano SC, Kim SW, Ker CG. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):83-90. Epub 2007 Jan 30.

Starting date: April 2008
Ending date: July 2009
Last updated: February 15, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012